Jon Lim is a Managing Partner who joined F-Prime in 2011 to launch our dedicated efforts in Healthtech + Services. His investments include F-Prime’s investments in Liazon (acquired by Towers Watson), PatientPing (acquired by Appriss Heath, now Bamboo Health), VitalWare (acquired by Health Catalyst), Artemis Health (acquired by Nomi Health), Lumere (acquired by Global Healthcare Exchange), Blue Rabbit (acquired by Wedgewood Pharmacy), Protenus (acquired by Bluesight), Benchling, BenchSci, Centivo, Equip Health, Kyruus, NOCD, OncoveryCare, Proximie, Rippl, TraceLink, US HealthVest and WelbeHealth. Jon was previously a Principal at Polaris Partners, where he was part of the teams that led investments in Phytel (acquired by IBM), Egnyte, Recurly, and Ocular Therapeutix (NASDAQ: OCUL). Jon began his investing career in 2002 as an Associate at Summit Partners, where his investments include MDVIP (acquired by Procter & Gamble) and Diagnostic Hybrids (acquired by Quidel). Jon also worked previously at Medtronic in their cardiac rhythm and disease management business.

Jon holds an M.B.A. from Harvard Business School and an A.B. in East Asian Studies from Harvard College, where he graduated magna cum laude.